Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

09 Feb 2009
Full Year 2008 results date notification – 19 February 2009

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce full year 2008 earnings on Thursday 19 February 2009.

- Results press release will be issued at: 12:00 GMT / 07:00 EST
- Investor meeting and conference call time: 14:00 GMT / 09:00 EST  

Investor & Analyst meeting and conference call:
Angus Russell, Chief Executive Officer, Graham Hetherington, Chief Financial Officer, Mike Cola, President, Specialty Pharmaceuticals and Sylvie Grégoire, President, Human Genetic Therapies will host the investor and analyst meeting and conference call at 14:00 GMT/9:00 EST.

The meeting will take place at the offices of Deutsche Bank, Winchester House, 1 Great Winchester Street, London, EC2N 2DB.

Please email Souheil Salah to register to attend this meeting in London.

The details of the conference call are as follows:

UK and International dial in: 44 (0)20 7806 1957
US dial in: 1 718 354 1388
Password/Conf ID: 9465839
Live Webcast
Replay: a replay of the presentation will be available for two weeks by phone and by webcast for one year. Details are as follows:

UK and International dial in: 44 (0)20 7806 1970
US dial in: 1 718 354 1112 Pin code: 9465839#
Webcast Replay

For further information please contact:

Investor Relations
Souheil Salah +44 1256 894 160
Ricki Greenwood +1 (484) 595-8517

Notes to editors

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website:

09 Feb 2009 Full Year 2008 results date notification – 19 February 2009 (17KB PDF)

« Back to Shire news

Did you know...

We have developed a
version of this web site
that is suitable for your
portable device